

aa⁸³ is G or R;

aa⁸⁴ is a hydrophobic or small amino acid;

wherein

D³ concl.

the sequence in the brackets may optionally be absent or truncated at any peptide type bond within the brackets may be used by themselves or in combination with immunosuppressant drugs, to reduce CTL activation, particularly in association with transplantation.

Remarks

The printed Sequence Listing filed March 19, 1997 is identical to the Sequence Listing submitted in machine-readable form filed on the same day.

This paper is submitted to comply with the United States Patent Office rules governing gene sequences and provide corrections to the previous amendment. No new matter is added.

It appears that the prior amendment filed on March 19, 1997 directing entry of SEQ ID NOs was inadvertently based upon a shift of page and line positions from those of the Office's copy. This corrected amendment seeks to only amend the page and line numbers at which each of the previously filed SEQ ID NOs were requested entered in the specification and the claims.


None of the sequences as originally filed has been amended by this amendment. However, it is noted that two incorrect characterizations of those sequences appear to have been made in the amendment filed March 19, 1997. SEQ ID NO:10 (at page 21, line 11) represents "B2702.75-84L⁸¹", not "B2702.75-84T⁸¹". Also, SEQ ID NO:31 (at page 21, line 17) should be recited, rather than the first recitation of SEQ ID NO:32. Applicants' undersigned representative regrets any inconvenience this may have caused and appreciates the Examiner bringing this matter to his attention.

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our Deposit Account No. 03-1952. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 10, 1998

Respectfully submitted,

By:


Thomas D. Mays, Ph.D., J.D.
Registration No. 34,524

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 887-8761
Facsimile: (202) 887-0763